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Abstract: The Antarctic deep-sea sponge Latrunculia (Latrunculia) biformis Kirkpatrick, 1908 (Class
Demospongiae Sollas, Order Poecilosclerida Topsent, Latrunculiidae Topsent) was selected
for chemical analyses due to its potent anticancer activity. Metabolomic analysis of its
crude extract by HRMS/MS-based molecular networking showed the presence of several
clusters of pyrroloiminoquinone alkaloids, i.e., discorhabdin and epinardin-type brominated
pyridopyrroloquinolines and tsitsikammamines, the non-brominated bis-pyrroloiminoquinones.
Molecular networking approach combined with a bioactivity-guided isolation led to the targeted
isolation of the known pyrroloiminoquinone tsitsikammamine A (1) and its new analog
16,17-dehydrotsitsikammamine A (2). The chemical structures of the compounds 1 and 2 were
elucidated by spectroscopic analysis (one-dimensional (1D) and two-dimensional (2D) NMR,
HR-ESIMS). Due to minute amounts, molecular modeling and docking was used to assess potential
affinities to potential targets of the isolated compounds, including DNA intercalation, topoisomerase
I-II, and indoleamine 2,3-dioxygenase enzymes. Tsitsikammamines represent a small class of
pyrroloiminoquinone alkaloids that have only previously been reported from the South African
sponge genus Tsitsikamma Samaai & Kelly and an Australian species of the sponge genus Zyzzya de
Laubenfels. This is the first report of tsitsikammamines from the genus Latrunculia du Bocage and
the successful application of molecular networking in the identification of comprehensive chemical
inventory of L. biformis followed by targeted isolation of new molecules. This study highlights the
high productivity of secondary metabolites of Latrunculia sponges and may shed new light on their
biosynthetic origin and chemotaxonomy.
Keywords: Antarctica; deep-sea; marine sponge; Latrunculia; molecular networking; molecular
docking; tsitsikammamine
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1. Introduction
Marine sponges are the richest and best-studied sources of bioactive marine natural products
(MNPs) among all marine organisms [1]. Sponges contribute to nearly 30% of all MNPs [2,3]. Antarctica
is considered as one of the most hostile environments on earth, with extremely cold temperatures,
long dark/light periods and low nutrients levels [4]. At the same time, it is one of the oldest,
environmentally stable and well-structured marine systems with a rich benthic community [5]. Sponges
are often highly diverse and dominant in the invertebrate communities of Antarctic ecosystems [6–8].
They provide structure to the benthos and nursery grounds for juvenile fish and many other
organisms [9]. In order to cope with harsh environmental conditions, to deter large predators such
as sea stars and nudibranchs, to avoid fouling and to ensure their survival in Antarctica, sponges
have developed a range of behavioral, physical and chemical defense mechanisms [6,10] including
the production of ‘antifreeze’ peptides [11] and unique, highly complex secondary metabolites [12,13].
While the majority of new therapeutic agents have been, and are sourced from tropical or temperate
oceans, Antarctica and the polar regions generally, are largely unknown from this standpoint [14,15],
due to issues of access.
Until recently, the sponge family Latrunculidae Topsent (Class Demospongiae Sollas,
Order Poecilosclerida Topsent) comprised five key genera: Latrunculia du Bocage, Strongylodesma Lévi,
Sceptrella Schmidt, Tsitsikamma Samaai & Kelly and Cyclacanthia Samaai, Govender & Kelly [16–18];
Bomba Kelly, Reiswig & Samaai and Latrunclava Kelly, Reiswig & Samaai were recently discovered
in the North Pacific [19]. From a thorough taxonomic re-evaluation of the various genera in which
pyroloquinolines have been found and of other compounds attributed to Latrunculiidae genera [20],
definitive new taxonomic conclusions were able to be drawn, resulting in the greater integrity of
Latrunculiidae (separating it from Podospongiidae), and the establishment of new genera within
Latrunculiidae [18,20].
Various subclasses of pyrroloiminoquinone alkaloids are represented in latrunculid sponges.
Latrunculia species are predominantly distributed in cold-water regions along the coasts and on
the continental shelfs of New Zealand, South Africa, Antarctica, and the North Pacific [17–19].
Since the first report of discorhabdin C, a brominated pyridopyrroloquinoline alkaloid from
a New Zealand Latrunculia sp. in 1986 [21], this genus has emerged as a prolific source of
discorhabdins [22–25]. The core tetracyclic iminoquinone chromophore renders discorhabdins
and many other pyrroloiminoquinone alkaloids highly coloured, producing the diagnostic deep
emerald and olive greens, and brick red coloration of many Latrunculia sponges in life [26].
Discorhabdin pigments have been shown to be located in the outer layers of the Antarctic
sponge species Latrunculia (Latrunculia) apicalis Ridley & Dendy, and linked to antifouling
activity and the chemical defense of the sponge against the spongivorous sea star Perknstar
fuscus [27]. Besides discorhabdins, the genus Latrunculia has repeatedly been reported to contain
makaluvamines (pyrroloiminoquinones), epinardins (pyridopyrroloquinolines) and makaluvic acids
(pyrroloquinoline) [28,29]. Tsitsikammamines that possess a non-brominated bis-pyrroloiminoquinone
scaffold represent another group of pyrroloiminoquinone alkaloids that are closely related to
discorhabdins. This small alkaloid family has only been reported from the South African latrunculid
sponge Tsitsikamma favus [28,30] and an Australian Zyzzya sp. [31]. Tsitsikammamines have previously
been suggested to represent biosynthetic intermediates between discorhabdins and makaluvamines,
and as chemotaxonomic markers for the genus Tsitsikamma [28,30]. A potential microbial origin
of tsitsikammamines is currently being debated [32,33]. Discorhabdins exhibit strong anticancer
activities by inhibiting the interaction of the cancer target HIF-1α (hypoxia-inducible factor 1alpha)
with p300 [34]. The anticancer activity of the natural tsitsikammamines has been linked to DNA
intercalation and inhibition of topoisomerase I and II enzymes [28], while synthetically prepared
tsitsikammamines and derivatives have been shown to inhibit indoleamine 2,3-dioxygenase (TDO1)
and tryptophan 2,3-dioxygenase (TDO) enzymes [35,36].
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As part of our recent project involving chemical and biological investigations of Antarctic
deep-sea sponges, the crude extract of L. biformis, which was collected from the Antarctic Weddell
Sea shelf at -303 m depth was found to show significant anticancer activity against six cancer cell
lines. A comprehensive dereplication study employing HRMS/MS-based molecular networking
(MN) allowed the identification of several molecular clusters in the crude extract, including a large
cluster composed of discorhabdins and epinardins, as well as a small tsitsikammamine cluster.
By using a combination of MN and anticancer activity-guided isolation, we obtained two minor
tsitsikammamine-type alkaloids, namely the known compound tsitsikammamine A (1) and its new
dehydro-analog 16,17-dehydrotsitsikammamine A (2) from L. biformis. Their structures were elucidated
on the basis of high-resolution spectroscopic methods (NMR and HR-ESIMS) and by comparison
with data reported in the literature. Since the amounts of the pure compounds were very minor
excluding any possibility for bioactivity testing, we used a structure based docking approach against
several cancer targets reported for 1, namely DNA intercalation, topoisomerase I-II, and indoleamine
2,3-dioxygenase (IDO1) enzymes, to predict anticancer potential of 1 and 2. Docking represents
an established method in drug discovery projects enabling insights into molecular ligand-protein
interactions. This is the first report of tsitsikammamine type alkaloids from a species of Latrunculia
and highly the successful application of MN in metabolome analysis and targeted isolation of new
molecules from a complex sponge extract.
2. Results
2.1. Molecular Networking-Based Dereplication
The dark green-colored sponge material was freeze-dried and successively extracted with water,
MeOH and DCM. The organic extracts were combined and submitted to bioactivity screening against
six cancer cell lines. The high anticancer activity of the crude extract (IC50 values from 0.8 to 6.3 µg/mL,
Table 1) prompted us to undertake a detailed chemical profiling on the crude sponge extract.
Table 1. Anticancer activity of Latrunculia biformis crude extract and fraction 3 that yielded
tsitsikammamines. The IC50 values are in µg/mL. Positive control doxorubicine.
Sample A-375 HCT-116 A-549 MB-231 Hep G2 HT-29 HaCaT
Crude extract 2.5 0.8 6.3 3.3 2.4 2.3 3.0
Fraction 3 4.3 1.2 5.0 5.6 5.1 5.2 6.5
Positive control 0.13 10.6 31.4 15.2 14.6 3.0 -
In order to achieve an in-depth dereplication of the known compounds and to prioritize the
isolation workflow towards putatively undescribed molecules, the crude extract of L. biformis was
analysed by tandem UPLC-QToF-MS/MS (positive-ion mode). The MS/MS (MS2) data were uploaded
to the publicly available Global Natural Product Social molecular networking (GNPS) platform (http:
//gnps.ucsd.edu) and analysed while using the molecular networking (MN) online workflow [37].
Molecular networking is a bioinformatics tool for dereplication of complex metabolomes, providing
visual displays of the chemical space present in MS2 experiments. The visualization approach by a
special software allows detection and grouping of sets of MS2 spectra from molecules (the so-called
spectral networks), which have similar structures with similar fragmentation patterns. In MN
visualization, each MS2 spectrum is represented as a node (compound) whereas spectrum-to-spectrum
alignments are shown as edges (connections) between nodes. The thicker the edge, the higher the
similarity between the nodes [38].
The composite MN of the crude L. biformis extract consisted overall of 90 nodes, which were
grouped into 22 clusters (at least two nodes per cluster) after subtraction of the nodes from the solvent
control (Figure 1). Some nodes represented isotopes or adducts, thus not all network nodes correspond
to a single molecule. Initially, the automated dereplication by comparison of MS2 fragmentation
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profiles with reference spectra from 25 spectral libraries on GNPS did not annotate any compounds.
This is not surprising because GNPS contains predominantly microbial metabolites and the availability
of data on sponge metabolites is limited in the GNPS spectral library. Hence after the generation of
the MN, a manual dereplication was performed by searching the predicted molecular formulae of
these nodes against several databases, such as Dictionary of Natural Products, MarinLit, Reaxys and
SciFinder. The Competitive Fragmentation Modeling for Metabolite Identification (CFM-ID) platform
(http://cfmid.wishartlab.com) was used to predict the fragments of a molecule and to distinguish
compounds with the same molecular formula. Taking the elemental composition, biological source
and the fragmentation pattern into consideration, this manual dereplication method allowed the
identification of three known pyrroloiminoquinone alkaloids discorhabdins G, Y, and tsitsikammamine
A (Figure 1).
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A detailed examination of the MN permitted annotation of the two main molecular families
(Figure 1). With 29 nodes, the first discorhabdin family (cluster A) was the biggest cluster with all
of the compounds being brominated. A detailed examination indicated this cluster to comprise
of three subfamilies (A1–A3) separated based on the number of bromine atoms and methoxy
substitution (Figure 1). The largest subfamily A2 contained only mono-brominated discorhabdi s. In a
database search, the molecular formula of one node at m/z 384.0340 (C18H1579BrN3O , [M + H]+)
corresponded to two molecules, discorhabdin E and G. Based on key fragments m/z 367.0300
(C18H1279BrN2O2), 357.0400 (C17H1479BrN2O2) and 304.1300 (C18H14N3O2) obtained by prediction on
CFM-ID platform, this node was rapidly annotated as discorh b in G (Figure 1). Anothe node at m/z
386.0390, ([M + H]+, C18H1779BrN3O2) also yielded two hits ( iscorhabdin Y and V) in the database
search. It was subsequently identified as discorhabdin Y based on the predicted MS fragments at
m/z 369.0200 (C18H1479BrN2O2), 359.0200 (C17H1679BrN2O2), 306.1400 (C18H16N3O2) and 277.1400
(C17H13N2O2). In addition, seven nodes were connected to discorhabdin G and eight nodes were linked
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to discorhabdin Y in the subfamily A2. However, none of these chemical formulae matched to any
known compound in the databases, indicating them to be potentially new discorhabdin derivatives.
The subfamily A1 (Figure 1) contained five nodes and it was identified as an epinardin subcluster,
separated from the subfamily A2 by bearing two bromine atoms and a methoxy function. Two nodes
with m/z [M + H]+ 416.0630 (C19H1979BrN3O3) and m/z [M + H]+ 491.9410 (C19H1679Br2N3O3) from
this subfamily had resulted in no hits in MarinLit, but based on similarity of their MS2 fragmentation
pattern on CFM-ID platform, these two nodes were identified as new derivatives of epinardin D m/z
494.9793 (C19H1979Br2N3O3) [39]. The node at m/z 416.0630 [M + H]+ was connected to two nodes in
subfamily A2, indicating its structural similarity to the discorhabdin subcluster. The other three nodes
in A1 were annotated as bromine isotope ions of these two compounds.
The subfamily A3 (Figure 1) was comprised of six nodes. One node with m/z [M + H]+ 459.9160
(C18H1279Br2N3O2) gave no match in MarinLit but the high similarity of its MS2 spectrum with
that of discorhabdin C (generated on CFM-ID) indicated it to be a new derivative of discorhabdin
C (m/z 460.9374, C18H1379Br2N3O2) [21]. The other five nodes in subcluster A3 were annotated as
isotope ions of this molecule. The second bromine atom in the subcluster A3 separated it from the
monobrominated discorhabdins in subfamily A2.
The second cluster (B) included five nodes, one of which with m/z 304.1250 (C18H14N3O2 [M + H]+)
was annotated as tsitsikammamine A [30]. This finding was unexpected because tsitsikammamines
have never previously been reported from the genus Latrunculia. In this cluster, we noted one node
with m/z 302.1110 (C18H12N3O2, [M + H]+), which was connected to that of tsitsikammamine A with
a very thick edge indicating a high structural similarity. The absence of a molecular formula match
to any known compound in the databases indicated this compound to be a putatively new analog
of tsitsikammamine A. The other nodes in cluster B were annotated as the minute isotope ions of
tsitsikammamine A and its new analog. There was no bromination in this cluster.
The remaining clusters (shown as grey networks in Figure 1) remained unidentified as they had
no match or MS2 fragment similarity to any known compound in multiple commercial or publicly
available databases. Hence they potentially represent new clusters and compounds. Interestingly,
no makaluvamine type of compounds were detected in the crude extract.
2.2. Purification and Structure Elucidation
The crude organic extract of the sponge that showed high activity against all six human cancer cell
lines (Table 1) was fractionated over an SPE cartridge to yield five main fractions. Fraction 3 (44 mg)
that retained the anticancer activity (IC50 values ranging from 1.2 to 5.6 µg/mL, Table 1) of the crude
extract and contained tsitsikammamines, discorhabdins and epinardins as determined by LC-MS
analyses, was given priority for chemical work-up. RP-HPLC separation of the fraction 3 yielded 33
sub-fractions. Tsitsikammamines were tracked in sub-fraction 8 (1.3 mg) while discorhabdins and
epinardins were tracked in sub-fraction 9 (2.4 mg). Further RP-HPLC purification of sub-fraction 8
yielded compounds 1 and 2 in very minor amounts. Although the remaining sub-fraction 9 had a
slightly higher amount, it was not worked up, due to the much higher diversity of discorhabdins
and epinardins.
The compound 1 was obtained as a greenish film. Its molecular formula C18H13N3O2 was
deduced by HR-ESIMS (m/z 304.1110 [M + H]+) indicating 14 degrees of unsaturation. The 1H NMR
spectrum in DMSO-d6 contained an AB system at δH 7.71 (2H, d, J = 8.5 Hz) and δH 6.70 (2H, d,
J = 8.5 Hz) indicating the presence of a para-disubstituted benzene ring, two aromatic resonances at
δH 7.14 (1H, d, J = 1.8 Hz) and δH 6.91 (1H, s), two triplets at δH 3.97 (2H, t, J = 7.8 Hz) and δH 2.65
(2H, t, J = 7.8 Hz), plus three exchangeable protons (δH 9.31, 12.00 and 12.28, all s) (Table 2, Figure S1).
The 13C NMR spectrum showed 16 carbon signals including two methylenes (δC 17.9 and δC 49.7),
four aromatic methines (δC 114.4, 121.2, 122.8, 129.8), nine quaternary carbons (δC 117.4, 121.6, 121.8,
124.3, 124.7, 125.1, 133.2, 154.1, 156.1) and a carbonyl group at δC 167.7 (Table 3, Figure S2). A detailed
analysis of the one-dimensional (1D) NMR data of 1 revealed high similarity to those reported for
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tsitsikammamine A (Figure 2), a nonbrominated bis-pyrroloiminoquinone alkaloid previously reported
from the South African sponge Tsitsikamma favus [28,30]. The main differences that were observed
between the two compounds stemmed from the chemical shifts of the region C12 through C20 and
were attributed to the fact that compound 1 was isolated as a free base whereas tsitsikammamine
A was obtained as an N-18 TFA salt [28,30]. The addition of one drop of TFA rapidly converted 1
into its TFA salt, upon which all 1H and 13C resonances became superimposable with those reported
for tsitsikammamine A (Tables 2 and 3; Figures S8 and S9). The only exception was the NMR data
of the para-disubstituted benzene ring that needed revision. Based on a strong NOESY correlation
with H-8 (δH 7.14, d, J = 1.8), two equal aromatic protons (δH 7.71) were assigned to H-1/H-5, which
was ascribed vice versa (as H-2/H-4) in the literature [30]. A full set of two-dimensional (2D) NMR
experiments was run to unambiguously confirm the tsitsikammamine scaffold. The key HMBC and
NOESY correlations observed are shown in Figure 3, Tables 2 and 3 display the complete NMR data of
1, as free-base and TFA salt in both DMSO-d6 and CD3OD. Hence compound 1 was unambiguously
characterized as tsitsikammamine A.
Table 2. 1H NMR data of compounds 1 (DMSO-d6 and CD3OD) and 2 (CD3OD) (600 MHz, δ in ppm).
Position
1 a 1 b 2 b
δH
c, Mult.
(J in Hz)
δH
d, Mult.
(J in Hz)
δH
e, Mult.
(J in Hz)
δH
c, Mult.
(J in Hz)
δH
c, Mult.
(J in Hz)
1 7.71 d (8.5) 6.87 d (8.4) 7.36 d (8.5) 7.50 d (8.5) 7.84 d (8.4)
2 6.70 d (8.5) 7.37 d (8.4) 6.86 d (8.5) 6.85 d (8.5) 6.85 d (8.4)
3
4 6.70 d (8.5) 7.37 d (8.4) 6.86 d (8.5) 6.85 d (8.5) 6.85 d (8.4)
5 7.71 d (8.5) 6.87 d (8.4) 7.36 d (8.5) 7.50 d (8.5) 7.84 d (8.4)
6
7
8 7.14 d (1.8) 7.16 d (2.5) 7.17 d (2.9) 7.02 s 7.22 s
NH-9 12.28 s 13.28 br s 13.32 s
10
11
12
NH-13 12.00 s 13.01 br s 13.04 s
14 6.91 s 7.10 d (1.8) 7.12 d (2.6) 6.91 s 7.93 s
15
16 2.65 t (7.8) 2.93 t (7.8) 2.93 t (7.8) 2.89 t (7.8) 7.66 d (5.9)
17 3.97 t (7.8) 3.85 t (7.8) 3.84 t (7.8) 3.94 t (7.8) 8.34 d (5.9)
19
20
21
OH 9.31 br s 10.60 br s 10.43 s
a DMSO-d6; b CD3OD; c free base; d data from literature [30]; e TFA salt.
Table 3. 13C NMR data of compounds 1 (DMSO-d6) and 2 (CD3OD) (150 MHz, δ in ppm).
Position
1 a 2 b,c
δC
d, Type δC e, Type δC f, Type δC d, Type
1 129.8, CH 116.2, CH 129.1, CH 129.8, CH
2 114.4, CH 128.9, CH 116.4, CH 114.4, CH
3 156.1, C 157.6, C 157.7, C 156.1, C
4 114.4, CH 128.9, CH 116.4, CH 114.4, CH
5 129.8, CH 116.2, CH 129.1, CH 129.8, CH
6 125.1, C 127.2, C 127.5, C 126.1, C
7 124.3, C 122.4, C 122.5, C 124.9, C
8 122.8, CH 125.0, CH 125.2, CH 123.1, CH
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Table 3. Cont.
Position
1 a 2 b,c
δC
d, Type δC e, Type δC f, Type δC d, Type
10 133.2, C 134.6, C 134.8, C 134.5, C
11 167.7, C 166.3, C 166.5, C n.o.
12 124.7, C 127.8, C 128.0, C 125.2, C
14 121.2, CH 123.1, CH 123.3, CH 123.9, CH
15 117.4, C 119.2, C 119.4, C 124.8, C
16 17.9, CH2 17.6, CH2 17.8, CH2 114.0, CH
17 49.7, CH2 45.0, CH2 45.0, CH2 140.6, CH
19 154.1, C 157.6, C 157.0, C 146.7, C
20 121.6, C 113.5, C 113.5, C 122.7, C
21 121.8, C 120.7, C 120.9, C 120.7, C
a DMSO-d6; b CD3OD; c Retrieved from HSQC and HMBC spectra; d free base; e data from literature [30]; f TFA salt;
n.o: not observed.
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The co pound 2 as also purified as a greenish film. The molecular formula C18H1 3
assigned to 2 by HR-ESIMS (m/z 302.0911 [M + H]+) indicated the presence of 15 degrees of unsaturation.
Comparison of the 1H-NMR data of 2 with those of compound 1 (Table 2) revealed a high resemblance,
with the only difference being the replacement of the methylene signals (H-16 δH 2.89 and -17 δ
3.94) with two olefinic signals (H-16, δH 7.66, d, J = 5.9 Hz and H-17, δH 8.34, d, J = 5.9 Hz) indicating an
unsaturation in 2. The key HMBC correlations (Figure 3) between H-16 and C-21 (δC 120.7); H-17 and
C-15 (δC 124.8), C-16 (δC 114.0) and C-19 (δC 146.7) indicated the position of the additional double bond
at ∆16. The strong COSY correlations between H-16 and H-17 confirmed this assignment. Our attempts
to locate the carbonyl carbon (C-11) using high-resolution cryoprobe or 1.7 mm microcryoprobe NMR
was unsuccessful, however, the structural homology as obvious from the 1H NMR and 2D NMR
data. Finally, the two mass unit difference between the molecular formulae of 1 and 2, as determined
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by HR-ESIMS data, clearly supported 2 being the ∆16 unsaturated analog of 1. Thus the chemical
structure of 2 was identified as 16,17-dehydrotsitsikammamine A (Figure 2). Compound 2 represents
the node that was identified above as a putatively new analog of tsitsikammamine A by molecular
network (cluster B, Figure 1).
2.3. Molecular Modeling and Docking
Both tsitsikammamines and discorhabdins have been reported to show potent anticancer activities
in vitro [28,30,40]. On a molecular level, DNA intercalation, topoisomerase I and II, indoleamine
2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO) enzymes have been identified
as potential targets for tsitsikammamines or their synthetic derivatives, while the inhibition of
HIF-1α/p300 interaction has been reported as potential target of discorhabdins [28,34–36]. Because
both compounds 1 and 2 were isolated in very little amounts, we were unable to test them
against any cancer cell lines or pursue any mechanistic studies with any of these enzymes. Hence,
in order to assess the potential anticancer activity of our compounds, we opted for a virtual
approach by molecular modeling (using Schrödinger software Maestro; www.schrodinger.com).
Where possible, based on suitable pdb structures, we performed docking experiments of compounds
tsitsikammamine A (1) and 16,17-dehydrotsitsikammamine A (2) within the binding sites of their
reported possible targets (topoisomerase I/II, indoleamine 2,3-dioxygenase IDO1). Thus, we prepared
available relevant pdb protein structures, removed the original ligands and generated receptor grids.
Small molecule three-dimensional (3D) structures of 1 and 2 were energetically minimized and possible
tautomers/protonated states were evaluated (LigPrep) to yield one compound structure each. Using
these optimized ligand structures, docking into the prepared respective active site was performed by
Glide XP [41]. Calculated 3D binding modes were illustrated, or presented as 2D ligand-interaction
diagrams, for clarity.
Docking of compound 2 into the active site of topoisomerase I (pdb 1T8I) [42] yielded plausible
binding modes (Figure 4). When compared to the original ligand camptothecin, the flat aromatic core
of 2 intercalates into the DNA part forming aromatic pi-pi-stacking interactions while addressing an
H-bond towards ASN 722 of the topoisomerase I protein. A similar binding pose was calculated for 1
in which the 16,17-dehydrotsitsikammamine scaffold is slightly distorted compared to 2 (not shown).
Similar results were obtained by docking experiments with topoisomerase II (pdb 3QX3, original ligand
etoposide) [43], likely indicating these proteins to be targets for marine derived tsitsikammamines 1
and 2.
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Figure 4. (A) Calculated three-dimensional (3D) binding mode of 2 in the crystallographically
determined active site of topoisomerase I (pdb 1T8I) also containing a DNA molecule (coloured
in red) with a single strand break. (B) Corresponding 2D ligand interaction diagram showing key
interactions of 2 to topoisomerase I and DNA. (C) Overlay of the binding pose of 2 (grey) with the
original ligand camptothecin (turquoise) indicating similar ligand space occupied by the scaffolds.
We next focussed on docking experiments with another reported target for tsitsikammamines,
namely the enzyme indoleamine 2,3-dioxygenase (IDO1) [36] for which valid structural data including
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ligand-protein complexes is also available. As the cofactor to mediate substrate oxidation IDO1
contains a heme moiety and ligands typically form interactions by complexing the Fe central atom.
Examples for such IDO1 inhibitors and relevant interacting moieties include NLG919 derivative
(imidazole-like nitrogen in pdb 5EK2) or ligand INCB14943 (hydroxylamidine moiety in pdb 5XE1).
Since 1 and 2 do not bear comparable nitrogen functionalities to be able to interact with heme in a
similar manner, docking of the compounds into these active sites revealed no plausible binding modes.
However, recent reports demonstrated that another class of potent IDO1 inhibitors such as FXB-001116
(pdb 6AZW) and BMS-978587 (pdb 6AZV) [44] bind to the IDO1 apo structure with high affinity,
thereby displacing the heme moiety. Accordingly, docking of 1 and 2 suggested possible binding
modes in the apo active sites of IDO1 (Figure 5) suggesting both compounds to be apo-IDO1 ligands.Mar. Drugs 2018, 16, 268 9 of 17 
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(not shown).
Inspecting the docking poses of tsitsikammamine A (1) and its derivative
16,17-dehydrotsitsikammamine A (2) in the above mentioned protein structures on a molecular level
suggests slight evidence for the role of unsaturation. Compound 2 shows a totally planar aromatic
core, which is somewhat conformationally twisted out of plane in the case of 1 having two sp3 carbon
atoms in the ethyl bridge. Thus, the total planar core of 2 preventing the ligand to access deeper into
the IDO1 binding pocket, addressing aromatic interactions towards front residues Phe163/Phe226,
and additionally forming an H-bond towards GLY262 within the solvent opening area. In contrast,
1 is actually filling the d ep lipop ilic pocket of IDO1, thereby not able to address an H-bond to
solv nt accessible residues. Interestingly, when ompared to 2, compound 1 is showing an about
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180◦ twisted core dominated by aromatic interactions to side chain residues Phe214/Phe270/Hie346.
However, structure-activity relationship studies (SARs) clearly pointed out the diminished cytotoxicity
in discorhabdins with ∆16 unsaturation [45,46]. The debated double bond of 2 is not part of an
electrophilic reactive α,β-unsaturated Michael acceptor system (“warhead”), which could covalently
attach to the binding site. While our molecular modeling approach suggested possible binding
interactions for 1 and 2 towards topoisomerases/DNA intercalation and IDO1, structural data for the
further possible targets such as tryptophan 2,3-dioxygenase (TDO) and HIF-1α/p300 protein was not
sufficient to draw analogous conclusions.
To our knowledge, this is the first molecular docking study performed on non-synthetic
tsitsikammamines. Based on the literature reports [28,30] and the activity profile of the crude extract
and the fraction 3 from which compounds 1–2 were isolated (Table 1, Figure S18), it is reasonable
to expect strong anticancer activity from both compounds. However, the IC50 values against the
non-cancerous human cell line (HaCaT) indicate that anticancer activity is associated with general
toxicity, which is common for pyrroloiminoquinone alkaloids [28]. Nevertheless, almost eight times
higher potency of fraction 3 against the human colon cancer cell line (HCT-116) points out to some
degree of selectivity.
3. Discussion
The identification and isolation of tsitsikammamines from a species of Latrunculia raises
questions regarding the origin of the tsitsikammamines. It should be noted that, the possibility
of a misidentification of the study material is rejected by the discovery of the unique spiculation
of the specimen under study, and is supported by the fact that the genus Tsitsikamma is endemic to
South Africa [32] and has not been reported from other Pacific, Atlantic or polar regions [19] that
harbour latrunculid sponges. It is also unlikely that the tsitsikammines are present, but undetectable,
at a broader taxonomic level of order (Poecilosclerida) or family (Latrunculiidae, Acarnidae) as the
Latrunculiidae, Acarnidae (Zyzzya most particularly), and Podospongiidae (previously integrated into
Latrunculiidae) are now amongst the earliest and best known of groups in the search for MNPs [18,20].
There are current debates on the natural origin of discorhabdins and tsitsikammamines. An early
biosynthetic study carried out by the group of Blunt and Munro [47] showed that discorhabdin B,
the principal cytotoxic pigment of a New Zealand Latrunculia sp., is of sponge origin, discounting
a microbial source for discorhabdins. In contrast, tsitsikammamines have been hypothesized to
have a microbial origin, and the sponge produced these compounds, T. favus, has been shown to
contain unusual bacterial taxa dominated by a novel Betaproteobacterium sp. [32]. A recent study
by Matcher et al. (2016) showed that several sponges belonging to genera Latrunculia, Tsitsikamma
and Cyclacanthia were dominated by the same Betaproteobacterium sp., suggesting that this bacterium
may have co-evolved with their latrunculid sponge hosts [33]. The Tsitsikamma and Cyclacanthia
sp. also contain a Spirochaetae OUT that was possibly acquired by the sponges recently from their
environments [33]. To our knowledge, there is no report on the symbionts of Zyzzya sp., although
tsitsikammamine C was discovered in an Australian Zyzzya sponge [31]. Hence the question regarding
the true natural origin of tsitsikammamines remains open.
So far only five tsitsikammamines are known in the literature, i.e., tsitsikammamines A, B, C and
the N-18 oximes of tsitsikammamine A and B. The N-18 oximes have been suggested as artifacts of
tsitsikammamines A, B formed during the isolation process [28]. Taboada et al. (2010) have briefly
mentioned the presence of tsitsikammamine A in Latrunculia brevis in 2010 [48], but this information
was cited as unpublished data without a subsequent publication. So by now, tsitsikammamine A, B,
and their N-18 oximes have only been ‘officially’ reported from one single South African Tsitsikamma sp.,
T. favus and exhibit anticancer activity [28]. Tsitsikammamine C that was reported from an Australian
Zyzzya sponge [31] exerts antimalarial activity. The current study adds 16,17-dehydrotsitsikammamine
A (2), as the sixth member of this small family with potential anticancer activity as determined by
molecular docking studies with enzyme targets previously reported for tsitsikammamines.
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MS/MS-based molecular networking is gaining enormous popularity among the natural product
community, enabling efficient metabolomics and dereplication of molecular clusters in complex
extracts and fractions. This computer-based approach is highly advantageous and superior to classical
metabolomics, because instead of identifying single metabolites, it characterizes and groups large
number of related new, known or new derivatives of known family of compounds in multiple molecular
families (networks) giving clues on exhaustive chemical inventory of a biological organism. MN is a
versatile method that has been used in many areas including drug discovery, ecology, microbiology,
and biosynthesis [38,49,50]. The current study confirms that MN has an outstanding potential in
chemotaxonomical studies by efficiently mapping the chemical space of a biological organism and
clearly clustering highly related subfamilies of the pyrroloiminoquinone scaffold by skeletal features
(e.g., tsitsikammamines as non-brominated bis-pyrroloiminoquinones) and substitution patterns
(discorhabdins and epinardins with mono-/di-bromination, or methoxy substutition). Although only
a small amount of sponge biomass was available as a starting material, HRMS2-based MN allowed for
us to distinguish, group and accurately visualize these subfamilies based on their structural similarities.
Furthermore, it enabled rapid and targeted isolation of tsitsikammamines from the Latrunculia sponge.
The MN showed that L. biformis extract contains many new discorhabdins and epinardins (subclusters
A1–A3) and even additional molecular clusters (shown in grey colours in Figure 1) that could not be
annotated to any scaffold. Hence they may potentially be new classes of natural products.
The taxonomy and systematics of the family Latrunculiidae has been complex and
controversial [18,51,52], and the arrangements in the family are still being refined [19]. However,
L. biformis is easily recognisable due to the possession of an additional form of anisodiscorhabd with a
long apical spine, and it has been described from different sites around Antarctica and the Shetland
islands [17,53]. Only a single report on the fatty acid composition of this species is known [54];
to our knowledge, this is the first study investigating the rich pyrroloiminoquinone content of this
species. The presence of tsitsikammamines, in addition to discorhabdins and epinardins in L. biformis,
indicates very close and complex biosynthetic relationships of the pyrroloiminoquinone alkaloids
among latrunculid sponges, warranting in-depth chemical, biosynthetic and microbiological studies.
Following our discovery and structural elucidation, solid SAR studies for 1 and 2 will reveal their
potential as pharmacologically relevant inhibitors.
4. Materials and Methods
4.1. General Procedures
NMR spectra were obtained on a Bruker AV 600 spectrometer (600 and 150 MHz for 1H and
13C NMR, respectively, Bruker®, Billerica, MA, USA) equipped with 5.0 mm Shigemi tube (SHIGEMI,
Co., LTD., Tokyo, Japan) or a Bruker Avance III spectrometer (500 and 125 MHz for 1H and 13C NMR,
respectively, Bruker®, Billerica, MA, USA) equipped with a 1.7 mm TCI MicroCryoProbe (Bruker®,
Billerica, MA, USA). The residual solvent signals were used as internal references: δH 3.31/δC 49.0 ppm
(MeOD), and δH 2.50/δC 39.51 ppm (DMSO-d6). 4-Dimethyl-4-silapentane-1-sulfonic acid (DSS) served
as the internal standard. High-resolution MS2 data were recorded on a Waters Xevo G2-XS QTof Mass
Spectrometer (Waters®, Milford, MA, USA) coupled to a Waters Acquity I-Class UPLC system (Waters®,
Milford, MA, USA). HR-ESIMS was recorded on micrOTOF II-High-performance TOF-MS system
(Bruker®, Billerica, MA, USA) equipped with an electrospray ionization source. Solid phase extraction
(SPE) was performed on the Chromabond SPE C18 column cartridges (6 mL/2000 mg, Macherey-Nagel,
Duren, Germany). HPLC separations were performed on a VWR Hitachi Chromaster system (VWR
International, Allison Park, PA, USA) consisting of a 5430 diode array detector (VWR International,
Allison Park, PA, USA), a 5310 column oven, a 5260 autosampler and a 5110 pump combined in parallel
with a VWR Evaporative Light Scattering Detector (ELSD 90, VWR International, Allison Park, PA,
USA). The eluents that were used for HPLC separations were 20 mM NH4CHOO water solution (A)
and MeCN (B). Routine HPLC separations were performed on semipreparative (Onyx, 100 × 10 mm,
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Phenomenex, Torrance, CA, USA) C18 Monolithic column and analytic (SeQuant®, 250 × 4.6 mm,
Merk, Germany) ZIC-HILIC column. The organic solvents that were used for UPLC-QToF-MS/MS
analyses were ULC/MS grade (Biosolve BV, Valkenswaard, The Netherlands) and HPLC grade (ITW
Reagents, Germany) for HPLC isolation processes. The water used was MilliQ-water produced by
Arium® Water Purification Systems (Sartorius, Germany).
4.2. Sponge Material
The green sponge was collected by Daniel Kersken (Senckenberg Research Institute and Natural
History Museum), with an Agassiz trawl at a depth of 303 m in the Weddel Sea, Antarctica
(70.892◦ S-11.130◦ W) on December 2015, during the scientific expedition PS96 (RV POLARSTERN).
Taxonomic examination of the spicule complement and dimensions revealed two forms of
anisodiscorhabd spicules, one of which has a well-developed spined apical projection, and which
is diagnostic for the well-known Antarctic and Southern Ocean sponge species [53], Latrunculia
(Latrunculia) biformis Kirkpatrick, 1908 (Class Demospongiae Sollas, Order Poecilosclerida Topsent,
Latrunculiidae Topsent) [55]. A reference specimen has been deposited at Senckenberg Research
Institute and Natural History Museum, Germany, under the accessing number SMF 12106.
4.3. Extraction and Isolation
The sponge tissue (19.141 g, frozen weight) was cut into small pieces and then dried using a
freeze-drier (Martin Christ, Germany). The lyophilized biomass (4.651 g) was extracted at room
temperature with water (3 × 200 mL) under agitation to yield the aqueous extract (E1, 1.590 g).
The sponge residue (3.019 g, dry weight) was subsequently extracted with MeOH (3 × 150 mL),
and then with dichloromethane (DCM, 3 × 150 mL) under the same conditions. The MeOH and
DCM extracts were combined and evaporated to dryness by a rotary evaporator to yield the organic
extract (172 mg). The organic extract showed very strong cytotoxicity against multiple cancer cell
lines. 152 mg of the organic extract was fractionated on a Chromabond SPE C18 cartridge. The elution
with a step gradient MeOH:H2O mixture (0% to 100%) afforded 5 fractions. Anticancer activity was
tracked to fraction 3 (F3 44 mg), which contained tsitsikammamines, discorhabdins and epinardins.
40 mg of F3 was further subjected to semi-prep. RP-HPLC chromatography equipped with Onyx
Monolithic C18 column using H2O/MeCN as the mobile phase. The sub-fractions were collected by
their UV absorption at 254 nm (every 1 min if no UV absorption was detected) to yield 33 sub-fractions
(F3-1 to F3-33). The tsitsikammamines were tracked in F3-08 (1.3 mg) that was further purified by
HPLC coupled to analytic SeQuant® ZIC-HILIC column eluted with mobile phase 20 mM NH4CHOO
water solution (A) and MeCN (B) to yield compound 1 (0.2 mg, tR 3.9 min) and 2 (0.1 mg, tR 3.2 min).
Discorhabdins and epinardins were tracked in sub-fraction 9 (2.4 mg). Although this sub-fraction had
a slightly higher amount, it was very rich in many discorhabdins and epinardins, hence, it was not
worked up.
Tsitsikammamine A (1): Greenish film; 1H NMR (DMSO-d6 and CD3OD, 600 MHz) and 13C NMR
(DMSO-d6, 150 MHz) Tables 2 and 3; HR-ESIMS found m/z [M + H]+ 304.1110, C18H14N3O2 requires
304.1081.
16,17-Dehydrotsitsikammamine A (2): Greenish film; due to minor amounts available, no UV and IR
data were recorded; 1H NMR (CD3OD, 600 MHz) and 13C NMR (CD3OD, extracted from the HMBC
spectrum 500 and 125 MHz) Tables 2 and 3; HR-ESIMS found m/z [M + H]+ 302.0911, C18H12N3O2
requires 302.0924.
4.4. UPLC-QToF-MS/MS Analysis
The crude organic extract was analyzed on an ACQUITY UPLC I-Class System coupled to the Xevo
G2-XS QToF Mass Spectrometer (Waters®, Milford, MA, USA) equipped with an electrospray ionization
(ESI) source operating with a positive polarity at a mass range of m/z 50–1600 Da. The 0.1 mg/mL
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MeOH solution of the organic extract was filtered through a 0.2 µm PTFE syringe filter (Carl Roth,
Karlsruhe, Germany) and then injected (injection volume: 1.0 µL) into the system that was equipped
with Acquity UPLC HSS T3 column (High Strength Silica C18, 1.8 µm, 100 × 2.1 mm I.D., Waters®)
operating at 40 ◦C. Separation was achieved with a binary LC solvent system controlled by MassLynx®
(version 4.1) using mobile phase A 99.9% water/0.1% formic acid (ULC/MS grade) and B 99.9%
ACN/0.1% formic acid (ULC/MS grade), pumped at a rate of 0.6 mL/min with the following gradient:
initial, 1% B; 0.0–6.0 min to 30% B; 6.0–11.5 min to 100% B; 11.5–13.5 min 100% B, and a column
reconditioning phase until 15 min.
ESI conditions were set with the capillary voltage at 0.8 kV, sample cone voltage at 40.0 V, source
temperature at 150 ◦C, desolvation temperature at 550 ◦C, cone gas flow in 50 L/h and desolvation gas
flow in 1200 L/h. MS/MS setting was a ramp collision energy (CE): low CE from 6 eV to 60 eV and
high CE from 9 eV to 80 eV. As a control, solvent (methanol) was injected. MassLynx® (Waters®, V4.1)
was used to analyze the achieved MS and MS2 data.
4.5. Molecular Networking
The network was created using the UPLC-HRMS/MS data generated from the crude extract
of L. biformis. All raw MS/MS data were converted from files (.raw) to mzXML file format using
MSConvert (version 3.0.10051, Vanderbilt University, USA). The converted data files were uploaded
to the Global Natural Products Social molecular networking (http://gnps.ucsd.edu) platform using
FileZilla (https://filezilla-project.org/) and a molecular network was generated while using the online
workflow [37]. The data were filtered by removing all MS/MS peaks within ±17 Da of the precursor
m/z. MS/MS spectra were window filtered by choosing only the top 6 peaks in the ±50 Da window
throughout the spectrum. The data was then clustered with MS-Cluster with a parent mass tolerance of
0.1 Da and a MS/MS fragment ion tolerance of 0.05 Da to create consensus spectra. Further, consensus
spectra that contained less than one spectrum were discarded. A network was then created where
edges were filtered to have a cosine score above 0.65 and more than four matched peaks. Further edges
between two nodes were kept in the network if and only if each of the nodes appeared in each other′s
respective top eight most similar nodes. The spectra in the network were then searched against GNPS
spectral libraries. The library spectra were filtered in the same manner as the input data. All of the
matches kept between network spectra and library spectra were required to have a score above 0.7 and
at least six matched peaks [37]. The output molecular networking data were analysed and visualized
using Cytoscape (ver. 3.4.0) [56].
4.6. Cytotoxicity Assay
Crude extract of L. biformis and downstream fractions were tested in vitro at a final concentration
of 200 µg/mL against six human cancer cell lines, Hep G2 (liver cancer cell line, DSMZ, Braunschweig,
Germany), HT29 (colorectal adenocarcinoma cell line, DSMZ, Braunschweig, Germany), A375
(malignant melanoma cell line, CLS, Eppelheim, Germany), HCT116 (colon cancer cell line, DSMZ,
Braunschweig, Germany), A549 (lung carcinoma cell line, CLS, Eppelheim, Germany), MDA-MB231
(human breast cancer line, CLS, Eppelheim, Germany) and the non-cancerous human keratinocyte
cell line HaCaT (CLS, Eppelheim, Germany). By monitoring the metabolic activity at 37 ◦C under
a humidified atmosphere and 5% CO2 in CellTiterBlue Cell Viability Assay (Promega, Mannheim,
Germany), the sensitivity of the cell lines to the crude extract or fractions was evaluated. Cells were
maintained in RPMI 1640 medium (Life Technologies, Darmstadt, Germany) with 10% fetal bovine
serum, 100 U/mL penicillin and 100 mg/mL streptomycin supplemented at 37 ◦C and 5% CO2.
The cells were seeded in 96 well plates at a concentration of 10,000 cells per well for bioactivity
tests. A stock solution of 40 mg/mL in DMSO was prepared for each extract. After 24 h incubation,
the medium in the cells was replaced by 100 µL fresh medium containing the test samples. All of the
samples were prepared in duplicates. Doxorubicin was used as positive control, while 0.5% DMSO and
growth media served as negative controls. After addition of the crude extracts, cells were incubated
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for 24 h at 37 ◦C. The assay was performed according to the manufacturer’s instructions (Promega).
Cells were incubated for 2 h at 37 ◦C. Fluorescence at an excitation wavelength of 560 nm and emission
at 590 nm was measured using the microplate reader Infinite M200 (Tecan, Crailshaim, Germany).
For the determination of IC50 values, a dilution series of the extracts or fractions were tested while
following the same procedure as described before. IC50 values were calculated by using Excel to
determine the concentration that show 50% inhibition of the viability.
4.7. Molecular Modeling and Docking
Molecular modeling was performed on a DELL Precision T3610 four core workstation using
Schrödinger Maestro, version 11.3, 2017, Schrödinger, LLC, New York, NY, USA. The following
RCSB protein data bank (pdb) crystal structures were used for modeling studies: 1T8I, 3QX3, 5EK2,
5XE1, 6AZV, 6AZW. Each protein structure was initially prepared by standard settings of the Protein
Preparation Wizard 2015-4 (Epik version 2.4, Schrödinger, LLC, 2015; Impact version 5.9, Schrödinger,
LLC, 2015; Prime version 3.2, Schrödinger LLC, 2015). For energy minimizations of the small molecule
ligands MacroModel, version 11.0, Schrödinger, LLC, 2015 was used. Ionization states and tautomers
were generated with LigPrep, version 3.6, Schrödinger, LLC, 2015. Ligand docking and receptor
grid generation was performed with Glide, version 6.9, Schrödinger, LLC, 2015. Figures and ligand
interaction diagrams (LID) were generated by Maestro.
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